First-Line Versus Second Or Further-Line Crizotinib For Trial Patients With Advanced Non-Small-Cell Lung Cancer Harboring Alk Rearrangements.
Jinji Yang,Yuanyuan Lei,Xuchao Zhang,Qing Zhou,Hong hong Yan,Hua-Jun Chen,Haiyan Tu,Zheng Wang,Chongrui Xu,Jian Su,Yi-sheng Huang,Bin-Chao Wang,Ben-Yuan Jiang,Xiao-Yan Bai,Wenzhao Zhong,Xue-Ning Yang,Yi-Long Wu
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.e19139
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:e19139 Background: No randomized controlled trials compared first-line to second-line crizotinib in advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. We aim to investigate progression-free survival (PFS), objective response rate (ORR) and overall survival (OS) of first-line versus second or further-line crizotinib for trial patients with advanced NSCLC harboring ALK rearrangements. Methods: From December 2010 to August 2014, 68 trial patients with advanced NSCLC harboring ALK rearrangements detected by fluorescence in situ hybridization (FISH) received crizotinib (250mg bid) treatment at Guangdong Lung Cancer Institute. Tumor response was assessed according to RECIST 1.1 criteria every six weeks. Retrospectively, PFS, ORR and OS were compared respectively between first-line and second or further-line crizotinib. Results: The last follow-up was on January 29, 2015. Median follow-up time was 33.8 months (95%CI, 21.4-46.1). There were 22, 29, 13, 2, and 2 patients in first, second, third, fourth and fifth-line crizotinib respectively. Median PFS (mPFS) was 13.8 months (95% CI, 7.6-19.9) in first-line, 6.8 months (95% CI, 0.6-13.0) in second-line, P= 0.007, and 7.0 months (95% CI, 3.8-10.2) in second and further-line crizotinib, P= 0.049. ORR was 81.8% (18/22), 72.4% (21/29), P= 0.429, and 69.6% (32/46), P= 0.273, respectively. OS data were not mature. Two-year survival rate was 65% (95% CI, 0.434~0.866),47% (95% CI, 0.274~0.666) and 50% (95% CI, 0.343~0.657) respectively. Conclusions: First-line was significantly superior to second or further-line crizotinib with respect to PFS in advanced NSCLC harboring ALK rearrangements. ORR was similar. However, randomized controlled trials are warranted in this setting.